Клещевой вирусный энцефалит в Томской области за последние 10 лет

In the given work had been lead the analysis of epidemiological data TBE for 1999—2009 on Tomsk area. The information on quantity imparted against tick-borne encephalitis, about results of research of pincers and blood at the persons who have addressed on points prevention of tick-borne encephalitis and about quantity of the diseased tick-borne encephalitis is presented. Analysis of a complex of preventive actions is spent. The reasons of formation of the long maintenance of a virus tick-borne encephalitis in blood are shown.Представлен анализ итогов эпидемических сезонов по клещевому энцефалиту 1999—2009 гг. по Томской области. Дана информация о количестве привитых против клещевого энцефалита, о результатах исследования клещей и крови у лиц, обратившихся на пункты серопрофилактики, и о количестве заболевших клещевым энцефалитом. Проведен разбор комплекса профилактических мероприятий. Показаны причины формирования длительного антигеноносительства вируса клещевого энцефалита

Клинико-иммунологическая характеристика больных клещевым энцефалитом в острый период в Томской области

Results of complex research of features of clinical and immunological profiles tick-borne encephalitis during the sharp period in Tomsk Region are resulted in the article. Last years redistribution of a parity of clinical displays of the sharp period in favor of prevalence of feverish forms of disease and a tendency to increase in cases of long circulation of an antigene of a virus tick-borne encephalitis is marked. One of the important reasons of such effect is decrease in immunological reactance of an organism with development of cytokine’s disbalance and expression infringement receptors of cytokines with lymphocytic cages.Представлены результаты комплексного исследования особенностей клинического и иммунологического профилей клещевого вирусного энцефалита в острый период в Томской области. В последние годы отмечаются перераспределение соотношения клинических проявлений острого периода в пользу преобладания лихорадочных форм заболевания и тенденция к увеличению случаев длительной циркуляции антигена вируса клещевого энцефалита. Одной из важных причин такого эффекта является снижение иммунологической реактивности организма с развитием цитокинового дисбаланса и нарушение экспрессии цитокинов рецепторов лимфоцитарными клетками

RISKS AND BENEFITS OF REPERFUSION STRATEGIES IN ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION

The review discusses various reperfusion strategies in patients with acute myocardial infarction with ST segment elevation (STEMI), based on the evidence from international clinical trials. The modern views on real-world invasive and conservative strategies of STEMI management in European countries are presented. The key factor for patients’ survival is the timing, not the method of reperfusion. The strategy of primary percutaneous coronary intervention (PCI) may fail to reduce mortality, if the door-to-balloon time is over 60 minutes, compared to immediate thrombolytic therapy (TLT). PCI is more effective than TLT only if the time difference (door-to-balloon vs. door-to-needle) is under 2 hours. The choice of reperfusion method should be based on the patient’s risk level. Primary PCI has limitations, since this method is not widely accessible, requires specially trained staff and special equipment. Early TLT is an acceptable standard method in STEMI management, highly applicable for the Russian clinical practice. However, in patients already treated with TLT, pharmaco-invasive strategy could be the method of choice. The description of thrombolytic drugs is focussed on the agents of II and III generations – alteplase (Actilyse®) and tenecteplase (Metalyse®), respectively. Before the introduction of Metalyse®, continuous infusion of Actilyse® was regarded as the gold standard of pharmacological reperfusion therapy. Recently, it has been shown that single-bolus Metalyse® therapy is as effective as continuous Actilyse® infusion, but with better safety profile. Pre-hospital TLT with single-bolus Metalyse® therapy (5-10 seconds) provides a unique clinical opportunity for early STEMI management and maximal myocardial rescue

Treatment of chronic heart failure with a very low dose of antibodies to C-fragment of type 1 angiotensin II receptor

The open randomized placebo-controlled prospective study was conducted; we documented improvement of global contractility and diastolic function of left ventricle, clinical and psychological status in 60 patients with chronic heart failure receiving a very low dose of antibodies to C-end fragment to AT1 receptors of angiotensin II for 6 months (Cardosten). The drug was well-tolerated